Artificial Intelligence
Global In Silico/Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (2020-2030)
Dublin, April 22, 2020 (GLOBE NEWSWIRE) — The “In Silico/Computer-Aided Drug Discovery Services Market: Focus on Large Molecules” report has been added to ResearchAndMarkets.com’s offering.
Over 30% of the total cost invested in developing a new drug can be saved by utilizing in silico services. However, this is highly variable and is dependent upon the nature of drug discovery projects.One of the key objectives of this report was to understand the primary growth drivers and estimate the future size of the in silico drug discovery services market. Based on several parameters, such as number of large molecules based drug discovery projects, adoption of in silico services for drug discovery and outsourcing profile, we have provided informed estimates on the likely evolution of the market for the period 2020-2030.The report also provides details on the likely distribution of the current and forecasted opportunity across:
[A] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization)[B] type of large molecule (antibodies, proteins, peptides, nucleic acids and vectors)[C] company size (small, mid-sized and large)[D] therapeutic area (autoimmune disorders, blood disorders, cardiovascular disorders, gastrointestinal and digestive disorders, hormonal disorders, HIV / AIDS, infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, skin disorders, urogenital disorders and others)[E] type of clientele (pharmaceutical / biotechnology companies and academic / research institutes)[F] key geographical regions (North America (the US and Canada), Europe (Italy, Germany, France, Spain and rest of Europe) and Asia-Pacific (China, India and Japan), along with the rest of the world)The process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in the range of USD 4-10 billion. Moreover, it is well-known that only a small proportion of leads, which are selected for further investigation during the initial stages of research, are actually translated into product candidates for clinical research studies. Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex than conventional small molecule drugs. As a result, there has been a direct rise in overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector.According to industry experts, almost 35% of the total cost and time invested in developing a new drug can be saved by adopting an in silico approach. As a result, companies offering in silico drug discovery services, such as computer-aided drug design (CADD), molecular modeling and quantitative structure-activity relationship (QSAR), have now become an important part of the pharmaceutical industry. In future, drug developers, especially those focused on the development of large molecules, are likely to continue relying on outsourcing for a significant part of their respective drug discovery and development operations.In addition to other elements, the report includes:A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.The report features detailed transcripts of discussions held with the following individuals (in alphabetical order):John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point)Sven Benson (Founder, candidum)Mark Whittaker (Senior Vice President, Evotec)Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)Companies Mentioned
16S TechnologiesAb StudioAbbVieAbCheckAbzenaAdagio PharmaceuticalsAdimabAdvent InternationalAjinomoto Bio-PharmaAllesh Biosciences LabsAllosterix PharmaceuticalsAmbrxAMRIAntitope (acquired by Abzena)AntiverseApconiXAprecia PharmaceuticalsAptuitAsiaVest PartnersAstraZenecaATHOS ServiceAvistron Chemistry ServicesBayer Animal HealthBDG LifeSciencesBenevolentAIBerkeley LightsBetta Biomedical Industry FundBIANABill & Melinda Gates FoundationBioAscentBioBench SolutionsBioclinicaBioDuroBioGlobal Consulting GroupBioNTechBiotech Investment GroupBIOTEMBMG LABTECHBroad Institute of MIT and HarvardBVCF ManagementCaldan TherapeuticsCALIXARcandidumCardioVascular Research FoundationCARLBioCatalent Pharma SolutionsCELLSCRIPTCharles River LaboratoriesChemBio Discovery SolutionsChemBridgeChemDivChemoGenics BioPharmaChemPartnerCloud PharmaceuticalsCompChem SolutionsConcept Life SciencesConifer PointConifer Point PharmaceuticalsCreative BiolabsCreative BiostructureCreative DiagnosticsCyclicaCyprotexDefense Advanced Research Projects AgencyDomainexDuPontEli LillyEuropean Investment BankEvotecFidelity Management & ResearchFidelta (a CRO Subsidiary of Galapagos)FormexFractal TherapeuticsFusion AntibodiesGenedata BiologicsGenentechGenevant SciencesGenmabGenomodelGenScriptGfree BioGreenpharmaHarlan LaboratoriesHarvard UniversityHiFiBiOHQL PharmaceuticalsIBM WatsonIcagenICONIDG CapitalImmunoPrecise AntibodiesIn-Cell-ArtInsilico MedicineInte:LigandIntegral MolecularInvusIRBMIronwood PharmaceuticalsIXTALJanssenJanus Henderson InvestorsJebsen CapitalJPT Peptide TechnologiesJubilant BiosysKeapstone TherapeuticsLakePharmaLead Discovery CenterLeadInvent TechnologiesLife TechnologiesMabVax TherapeuticsMascot IndustriesMerckMetropolis HealthcareMicar InnovationMIG FundsMind the ByteMirae AssetMolecular DevicesMolecular ForecasterMolecular ResponseMoleculomicsMolsoftN2 Business Growth FundNIHNovaData SolutionsNovAliXNovartisNovo InformaticsNuChem TherapeuticsNumerateNYU Langone HealthOscotecPacificGMPPatheonPathios TherapeuticsPeak ProteinsPelago BiosciencePepscanPeptonePfizerPharma InventorPharmaceleraPharmaciaPhoenix Equity PartnersPlatinum Asset ManagementPolyTherics (acquired by Abzena)Porton Pharma SolutionsPPDPrestwick Chemical (acquired by Bionomics)ProfacgenProMab BiotechnologiesProsarixProteinQureProteoGenixProvid PharmaceuticalsPX’TherapeuticsQIAGENQuantitative MedicineRASA Life Science InformaticsRedmile GroupRedX PharmaRocheRosaRosetta Design GroupRuiYiSai Life SciencesSandexisSandozSanofiSchering PloughSchrdingerShuwen BiotechSilcsBioSitryxSonnet BioTherapeuticsSosei HeptaresSteam Athena CapitalStruengmann Family OfficeSundia MediTechSygnature DiscoverySyngeneTaros ChemicalsTelix PharmaceuticalsThe Chemistry Research Solution (acquired by Abzena)Tmunity TherapeuticsTRIANNIUniversity of PennsylvaniaUPMViramatixVirtua DrugViva BiotechViva VisionWarwick Effect PolymersWuXi AppTecWyss InstituteYUMABZoBioZorilla ResearchFor more information about this report visit https://www.researchandmarkets.com/r/bvw9jvResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Artificial Intelligence
Flat Ads Makes Its Mark at DMEXCO 2024: Showcasing Strength in Programmatic Advertising
COLOGNE, Germany, Sept. 20, 2024 /PRNewswire/ — In September, Flat Ads makes its mark at DMEXCO 2024, the prestigious European event of digital marketing and technology. The highly successful exhibition boasts 650 exhibitors, 850 speakers, and thousands of participants. At the event, Flat Ads showcased the strength of programmatic advertising platform in ad delivery, traffic optimization, and brand safety.
Flat Ads programmatic advertising platform has an exclusive developer traffic of 700 million and an extensive network spanning over 200 countries and regions worldwide. It cooperates with over 200 leading DSP/SSP partners, including FreeWheel, PubMatic and Criteo, leveraging an efficient and complete bidding system, as well as automatic delivery algorithms, to achieve precise marketing and advertising effectiveness maximization.
With its exclusive platform strategy algorithm, Flat Ads programmatic advertising platform can continuously conduct automatic exploration and matching based on the characteristics of DSP and traffic, optimize and adjust the algorithm model in real-time. This not only ensures the sustainability of DSP budgets, but also maximizes traffic utilization and enhances monetization revenue of advertisements.
Moreover, brand protection is among the top priorities of Flat Ads. In addition to accessing to authority agency Pixalate to test the effectiveness of ads, it has also accessed HUMAN, the global cybersecurity authority to safeguard its clients by preventing bot attacks, digital fraud and abuse, ensuring a stable, reliable, and secure programmatic advertising transaction platform.
By participating in DMEXCO 2024, Flat Ads showcased its outstanding strength and fruitful achievements in the programmatic advertising field, attracting the attention of numerous advertisers and developers for cooperation. Flat Ads boasts not only robust technical capabilities and innovative prowess, but also an active and open attitude towards emerging technologies, embracing and exploring them. It remains committed to providing more professional and efficient global marketing services to advertisers and developers worldwide, helping clients stand out in the fiercely competitive market and achieve business growth.
As a globally leading mobile advertising marketing platform, Flat Ads currently operates offices in Singapore, Indonesia, Hong Kong, and Guangzhou, serving over 1000 clients with global marketing solutions. If you’re interested in Flat Ads’ programmatic advertising services, please visit www.flat-ads.com.
View original content:https://www.prnewswire.co.uk/news-releases/flat-ads-makes-its-mark-at-dmexco-2024-showcasing-strength-in-programmatic-advertising-302253872.html
Artificial Intelligence
Fraud Detection & Prevention Market to Reach $252.7 Billion, Globally, by 2032 at 24.3% CAGR: Allied Market Research
The introduction of big data analytics, cloud computing services, and an upsurge in mobile payment drive the growth of the market.
PORTLAND, Ore., Sept. 20, 2024 /PRNewswire/ — Allied Market Research published a report, titled, “Fraud Detection & Prevention Market by Component (Solution and Service), Deployment Mode (On-Premises and Cloud), Organization Size (Large Enterprises and Small and Medium-sized Enterprises) and Industry Vertical (BFSI, IT and Telecom, Retail, Healthcare, Government and Defense, Manufacturing, Transportation and Logistics and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032”. According to the report, the “fraud detection & prevention market” was valued at $29.5 billion in 2022, and is projected to reach $252.7 billion by 2032, growing at a CAGR of 24.3% from 2023 to 2032.
The introduction of big data analytics, cloud computing services, and an upsurge in mobile payment drive the growth of the market. In addition, the rise in the adoption of banking & financial sectors across the globe fuels the growth of the market. Moreover, continuous technological advancements are expected to provide lucrative opportunities for the growth of the market during the forecast period. On the contrary, the high cost of fraud detection and prevention solutions limits the growth of the fraud detection & prevention market.
Request Sample Pages: https://www.alliedmarketresearch.com/request-sample/2142
The solution segment held the highest market share in 2022.
By component, the solution segment dominated the market in 2022, this dominance is driven by the increasing demand for advanced technological solutions that can effectively detect, monitor, and prevent fraudulent activities across various industries such as banking, e-commerce, and insurance. Solutions like AI-based fraud detection, machine learning algorithms, and behavioral analytics have become critical tools in identifying potential fraud in real time and reducing financial losses. However, the service segment is expected to witness the largest CAGR of 28.0%, this growth is driven by the increasing need for specialized services such as consulting, implementation, and maintenance to help organizations effectively integrate and optimize fraud detection solutions.
The BFSI segment held the highest market share in 2022.
By industry vertical, the BFSI segment accounted for the largest share in 2022. This is primarily due to the high frequency and sophistication of fraud targeting financial institutions, making fraud detection and prevention solutions a critical need in the BFSI sector. Financial transactions, online banking, and digital payments are particularly vulnerable to cyberattacks, phishing schemes, and identity theft, driving the sector’s substantial investment in advanced fraud detection technologies. However, the retail segment is expected to witness the largest CAGR of 32.7%. This anticipated growth is driven by several factors. Retailers are increasingly targeted by fraudsters due to the high volume of transactions and the sensitivity of customer data involved. As e-commerce and digital transactions expand, the need for advanced fraud detection and prevention solutions becomes more critical.
Enquiry Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/2142
Regional Insights: The North America region held the highest market share in 2022.
By region, the fraud detection & prevention market was dominated by North America in 2022. North America, particularly the U.S., has a highly developed financial and technological infrastructure that supports advanced fraud detection solutions. The region’s significant investments in cybersecurity and fraud prevention technologies, combined with a high incidence of cyber threats, drive continuous innovation and adoption of sophisticated fraud management systems.
Buy this Complete Report (415 Pages PDF with Insights, Charts, Tables, and Figures) at:
https://www.alliedmarketresearch.com/fraud-detection-and-prevention-market/purchase-options
Key Industry Developments
In February 2024, the U.S. Department of the Treasury announced that it has recovered over $375 million as a result of its implementation of an enhanced fraud detection process that utilizes Artificial Intelligence (AI) at the beginning of Fiscal Year 2023.In April 2024, Cognizant collaborated with FICO, to launch a cloud-based real-time payment fraud prevention solution powered by FICO Falcon Fraud Manager. The joint offering would leverage both firms’ artificial intelligence (AI) and machine learning (ML) technology to help banks and other payment service providers in North America protect their customers from fraud in the growing world of instant digital payments.In September 2022, Deutsche Bank collaborated with Visa, to help prevent online retail fraud. Merchants who process their e-commerce payments via Deutsche Bank can now use “Decision Manager,” an automated fraud detection system from Visa-owned company Cybersource.AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports Insights” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:David Correa1209 Orange Street,Corporation Trust Center,Wilmington, New Castle,Delaware 19801 USA.Int’l: +1-503-894-6022Toll Free: +1-800-792-5285UK: +44-845-528-1300India (Pune): +91-20-66346060Fax: [email protected]
Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fraud-detection–prevention-market-to-reach-252-7-billion-globally-by-2032-at-24-3-cagr-allied-market-research-302253960.html
Artificial Intelligence
G42 Collaborates with NVIDIA to Deliver Next-Generation Climate Solutions Using Earth-2
ABU DHABI, UAE, Sept. 20, 2024 /PRNewswire/ — G42, a leader in AI and cloud computing, today announced that it is partnering with NVIDIA to advance climate technology with a focus on developing AI solutions aimed at dramatically enhancing the accuracy of weather forecasting globally.
The collaboration builds on NVIDIA’s Earth-2, an open platform that accelerates climate and weather predictions with interactive, AI-augmented, high-resolution simulation. G42 and NVIDIA will initially focus on a square-kilometer resolution weather forecasting model that improves the accuracy of meteorological predictions.
Key to this initiative is the establishment of a new operational base and Climate Tech Lab in Abu Dhabi. This state-of-the-art facility will serve as a hub for research and development, driving forward both companies’ commitment to environmental sustainability. This facility will also mobilize the creation of tailored climate and weather solutions that leverage over 100 petabytes of geophysical data assets.
Peng Xiao, Group CEO of G42, said, “This initiative with NVIDIA is a testament to our commitment to applying AI in ways that not only innovate but also solve critical global challenges. Establishing the Earth-2 Climate Tech Lab in Abu Dhabi allows us to leverage our unique capabilities and insights to foster a sustainable future for the world.”
In addition to fostering innovation in climate technology, the initiative will focus on building a robust framework for integrating enhanced weather prediction capabilities with comprehensive data metrics and visualization. This will assist organizations worldwide in achieving their sustainability goals through well-informed, data-driven environmental strategies.
“Our collaboration with G42 marks a pivotal step toward harnessing AI to understand and predict climate phenomena with unprecedented accuracy,” said Jensen Huang, founder and CEO of NVIDIA. “The Earth-2 Climate Tech Lab will propel environmental solutions using the most advanced accelerated computing and AI technology to benefit millions of people around the world.”
By uniting G42’s AI expertise with NVIDIA’s computational acumen, this partnership aims to deliver transformative climate solutions that combine scientific accuracy with real-world applicability, driving impactful change across industries and ecosystems.
About G42
G42 is a technology holding group, a global leader in creating visionary artificial intelligence for a better tomorrow. Born in Abu Dhabi and operating worldwide, G42 champions AI as a powerful force for good across industries. From molecular biology to space exploration and everything in between, G42 realizes exponential possibilities, today. To know more visit www.g42.ai.
Media contactsMedia and PR Team, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/g42-collaborates-with-nvidia-to-deliver-next-generation-climate-solutions-using-earth-2-302253818.html
-
Artificial Intelligence4 days agoDATAMARK Technologies Applauded by Frost & Sullivan for Advancing Location Determination Capabilities and Data Accuracy with Its Improved GIS and Indoor Mapping Solution
-
Uncategorized7 days agoSUBBD and Luna PR Join Forces to Shape the Future of AI-Powered Content Creation
-
Artificial Intelligence7 days agoGlobal AI Summit 2024 continued to transform data and AI landscape on final day
-
Artificial Intelligence7 days ago
Sinch calls for early redemption of outstanding bonds 2019/2024
-
Artificial Intelligence4 days agoLab Automation Market to Reach $11.31 Billion by 2031, Driven by Rising Pharmaceutical & Biotech R&D Expenditures and Increasing Demand for Automated Laboratories and Instruments – Report by Meticulous Research®
-
Artificial Intelligence7 days agoIT Operations Analytics (ITOA) Market worth $127.4 billion by 2029- Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence7 days agoUST Launches ‘UST Retail GenAI platform’ – Transforming Retail Operations with Generative AI-Driven Solutions
-
Artificial Intelligence7 days agoTelecommunications and BFSI Customer Engagement Solutions Market to Reach $16.1 billion, Globally, by 2032 at 8.7% CAGR: Allied Market Research
